Roivant Sciences (NASDAQ:ROIV) Issues Earnings Results, Beats Estimates By $0.57 EPS

Roivant Sciences (NASDAQ:ROIV) released its quarterly earnings results on Wednesday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57, FiscalAI reports. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 19.04% and a negative net margin of 6,079.94%.During the same quarter in the previous year, the company posted ($0.29) earnings per share.

Here are the key takeaways from Roivant Sciences’ conference call:

• Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with about 73% ACR20, over 50% ACR50, and more than one-third ACR70 responses in a heavily refractory population.
• The company said the RA data looked especially strong in the JAK- and TNF-refractory subgroup, and management emphasized that the treatment was safe and well-tolerated with no new drug-related safety signals identified.
• Roivant expects to use the RA results, along with additional patient-level analysis, to engage FDA on the future development path for IMVT-1402 later this year, including how many registrational studies may ultimately be needed.
• For mosliciguat in PH-ILD, management highlighted strong Phase I signals, including roughly 30% average PVR reduction and about 38% peak PVR reduction, with good tolerability and limited systemic side effects.
• Roivant said its PH-ILD Phase II study is fully enrolled at 135 patients, the vast majority reached the target dose, and topline data is expected in the second half of 2026; the company also reiterated a strong cash position of $4.3 billion pre-Moderna settlement.

Roivant Sciences Trading Down 3.0%

Shares of ROIV traded down $0.96 during mid-day trading on Thursday, hitting $31.45. The company’s stock had a trading volume of 1,164,918 shares, compared to its average volume of 6,031,146. Roivant Sciences has a 1-year low of $10.59 and a 1-year high of $32.79. The firm has a market capitalization of $22.51 billion, a P/E ratio of -27.02 and a beta of 1.14. The firm has a 50-day simple moving average of $28.43 and a 200 day simple moving average of $24.95.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Roivant Sciences in a report on Friday, May 8th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday. Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target for the company. Piper Sandler increased their price target on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Finally, TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $31.55.

Key Headlines Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant beat earnings expectations for the quarter, reporting an adjusted EPS of $0.28 versus consensus near a loss, helping drive investor optimism around the company’s improving profitability. Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
• Positive Sentiment: Management pointed to major near-term pipeline and business catalysts, including an anticipated $950 million Moderna-related payment in July and second-half 2026 readouts for mosliciguat and IMVT-1402. Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts
• Positive Sentiment: Investor sentiment was also supported by strength in Roivant affiliate Immunovant, whose trial results were described as clinically meaningful, reinforcing the value of Roivant’s broader biotech pipeline. 2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
• Neutral Sentiment: The quarter was not uniformly strong, as revenue missed estimates and the company remains unprofitable on a net basis, leaving some questions about the durability of the rally. Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
• Neutral Sentiment: Options activity showed unusually heavy put buying, suggesting some traders were hedging or betting on volatility around the earnings announcement.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the transaction, the director owned 15,804 shares in the company, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,345,173 shares of company stock valued at $65,251,917 in the last three months. Insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. grew its holdings in shares of Roivant Sciences by 24.0% in the 4th quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock worth $1,525,000 after acquiring an additional 13,609 shares during the period. Invesco Ltd. raised its holdings in Roivant Sciences by 28.9% during the fourth quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock worth $49,508,000 after purchasing an additional 512,129 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Roivant Sciences during the fourth quarter worth $227,000. Empowered Funds LLC purchased a new stake in Roivant Sciences during the fourth quarter worth $396,000. Finally, VestGen Investment Management purchased a new stake in Roivant Sciences during the fourth quarter worth $743,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.